文献速递免疫规划卫生政策与健康促进

疫苗佐剂效应与季节性前免疫状态的关联:比较角鲨烯佐剂与水性灭活流感疫苗的随机免疫原性试验的系统综述与Meta分析

Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines.
PubMed 文献 · Vaccine · 2019-12-24

该系统综述与Meta分析纳入1999至2017年发表的49项随机试验、22,470名各年龄段受试者,比较角鲨烯佐剂灭活流感疫苗与水性灭活流感疫苗的免疫原性。结果显示,佐剂效应与接种前血凝抑制抗体几何平均滴度及平均年龄呈负相关,在平均年龄小于2.5岁的幼儿中最明显,平均几何平均滴度比为3.7(95%CI 2.5至5.5),随年龄增长逐渐降至老年人的1.4(95%CI 1.0至1.9)。

要点

  • 佐剂效应与接种前GMT和平均年龄呈负相关。
  • 幼儿平均GMT比为3.7(95%CI 2.5至5.5),老年人降至1.4(95%CI 1.0至1.9)。
  • 异源滴定的佐剂效应同样在低年龄组更大。

核心结论

  • 角鲨烯佐剂灭活流感疫苗相对于水性灭活流感疫苗的免疫原性益处,在幼儿中最高,并随年龄增长而降低。
  • 该趋势在季节性流感各亚型及2009年大流行株中相似,同源与异源滴定均如此。

研究设计与样本

  • 系统综述与Meta分析,纳入1999至2017年发表的49项随机免疫原性试验,共22,470名符合条件、覆盖所有年龄段的受试者。
  • 多数疫苗每株含15微克病毒血凝素;佐剂疫苗每剂多含9.75毫克角鲨烯。
  • 记录290个单一流感(亚)型组的同源接种前后血凝抑制抗体几何平均滴度,佐剂效应以接种后GMT比值(GMTR)表示,共145个估计值。

主要发现

  • 对所有流感(亚)型,佐剂效应与接种前GMT及平均年龄呈负相关。
  • 幼儿(平均年龄小于2.5岁)佐剂效应最明显,平均GMTR为3.7(95%CI 2.5至5.5)。
  • 随年龄增长,GMTR逐渐下降,老年人降至1.4(95%CI 1.0至1.9)。
  • 模拟疫苗与流行病毒不匹配的异源抗体滴定(30个GMTR估计值)同样显示低年龄组佐剂效应更大。
  • 将GMT转换为抗体预测保护率后,保护率差异呈现与GMTR相似的年龄模式;乙型流感佐剂效应持续时间长于甲型,可能因乙型流感病毒暴露通常较晚。

临床怎么用

  • 原文讨论了接种前免疫状态对疫苗效果的影响及其对年龄特异性接种建议的意义,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immunogenicity benefit of inactivated influenza vaccine (IIV) adjuvanted by squalene over non-adjuvanted aqueous IIV was explored in a meta-analysis involving 49 randomised trials published between 1999 and 2017, and 22,470 eligible persons of all age classes. Most vaccines contained 15 μg viral haemagglutinin per strain. Adjuvanted IIV mostly contained 9.75 mg squalene per dose. Homologous pre- and post-vaccination geometric mean titres (GMTs) of haemagglutination-inhibition (HI) antibody were recorded for 290 single influenza (sub-)type arms. The adjuvant effect was expressed as the ratio of post-vaccination GMTs between squalene-IIV and aqueous IIV (GMTR, 145 estimates). GMTRs > 1.0 favoured squalene-IIV over aqueous IIV. For all influenza (sub-)types, the adjuvant effect proved negatively associated with pre-vaccination GMT and mean age. The adjuvant effect appeared most pronounced in young children (mean age < 2.5 years) showing an average GMTR of 3.7 (95% CI: 2.5 to 5.5). With increasing age, GMTR values gradually decreased towards 1.4 (95% CI: 1.0 to 1.9) in older adults. Heterologous antibody titrations simulating mismatch between vaccine and circulating virus (30 GMTR estimates) again showed a larger adjuvant effect at young age. GMT values and their variances were converted to antibody-predicted protection rates using an evidence-based clinical protection curve. The adjuvant effect was expressed as the protection rate differences, which showed similar age patterns as corresponding GMTR values. However for influenza B, the adjuvant effect lasted longer than for influenza A, possibly due to a generally later influenza B virus exposure. Collectively, this meta-analysis indicates the highest benefit of squalene-IIV over aqueous IIV in young children and decreasing benefit with progressing age. This trend is similar for seasonal influenza (sub-)types and the 2009 pandemic strain, by both homologous and heterologous titration. The impact of pre-seasonal immunity on vaccine effectiveness, and its implications for age-specific vaccination recommendations, are discussed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Beyer WEP, Palache AM, Reperant LA, et al. Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines. Vaccine. 2019. PMID: 31879122. doi:10.1016/j.vaccine.2019.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。